Posted by [ad_1]
Grandbrothers
Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for its drug nipocalimab in the treatment of antibody-positive patients with generalized myasthenia gravis.
Nipocalimab was also recently granted Breakthrough Therapy Designation by
[ad_2]